We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abiomed's Impella Ensures Higher Survival Rates, Shares Up
Read MoreHide Full Article
Abiomed, Inc.’s Impella Quality (IQ) Database recently showed a 24% increase in survival rates of patients from acute myocardial infarction (AMI) cardiogenic shock. Notably, this followed the FDA post-market approval of Impella to treat cardiogenic shock. Furthermore, the success rate nearly doubled at the number of hospital centers using Impella.
The latest development fortifies Abiomed’s hold in the cardiovascular devices market.
Following the announcement, shares of Abiomed rose 10% to $419.61 at close. Over the past year, the stock has skyrocketed 161.7% compared with the industry’s 29.2% rise. The current level is also higher than the S&P 500 index’s increase of 17.5%.
The stock currently has a Zacks Rank #3 (Hold).
Earlier, the Massachusetts-based MedTech giant announced that it will highlight the recently expanded FDA indications for Impella for treating high-risk PCI (percutaneous coronary intervention) and cardiogenic shock.
In fact, in July, Abiomed’s Impella 2.5, Impella CP and Impella 5.0 heart pumps received the Central Drugs Standard Control Organization (CDSCO) approval in India. (Read More: Abiomed Gets CDSCO Nod for Impella Heart Pumps in India)
About Impella
Impella, the world’s smallest heart pump, is Abiomed’s flagship product line. The company’s Impella 2.5, Impella RP, Impella 5.0 and Automated Impella Controller deserve a mention in this regard.
Notably, the product has been driving the company’s top line since inception.
In fact, in the last reported quarter, Impella adoption in the Protected PCI and cardiogenic shock indications grew 24% and 37%, respectively. Additionally, Impella contributed $2.6 million in revenues.
Market Prospects
Per research by CDC, nearly 610,000 people die from heart diseases each year in the United States.
Statista validates that the U.S. cardiovascular devices market is expected to reach $15.7 billion by 2021.
Thus, the latest development has been a well-timed one for Abiomed.
Key Picks
Some better-ranked stocks in the broader medical space are athenahealth , Masimo Corporation (MASI - Free Report) and Veeva Systems (VEEV - Free Report) .
Masimo’s long-term earnings growth rate is projected at 14.8%. The stock carries a Zacks Rank #2 (Buy).
Veeva Systems’ long-term earnings growth rate is estimated at 19.3%. The stock carries a Zacks Rank #1.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Abiomed's Impella Ensures Higher Survival Rates, Shares Up
Abiomed, Inc.’s Impella Quality (IQ) Database recently showed a 24% increase in survival rates of patients from acute myocardial infarction (AMI) cardiogenic shock. Notably, this followed the FDA post-market approval of Impella to treat cardiogenic shock. Furthermore, the success rate nearly doubled at the number of hospital centers using Impella.
The latest development fortifies Abiomed’s hold in the cardiovascular devices market.
Following the announcement, shares of Abiomed rose 10% to $419.61 at close. Over the past year, the stock has skyrocketed 161.7% compared with the industry’s 29.2% rise. The current level is also higher than the S&P 500 index’s increase of 17.5%.
The stock currently has a Zacks Rank #3 (Hold).
Earlier, the Massachusetts-based MedTech giant announced that it will highlight the recently expanded FDA indications for Impella for treating high-risk PCI (percutaneous coronary intervention) and cardiogenic shock.
In fact, in July, Abiomed’s Impella 2.5, Impella CP and Impella 5.0 heart pumps received the Central Drugs Standard Control Organization (CDSCO) approval in India. (Read More: Abiomed Gets CDSCO Nod for Impella Heart Pumps in India)
About Impella
Impella, the world’s smallest heart pump, is Abiomed’s flagship product line. The company’s Impella 2.5, Impella RP, Impella 5.0 and Automated Impella Controller deserve a mention in this regard.
Notably, the product has been driving the company’s top line since inception.
In fact, in the last reported quarter, Impella adoption in the Protected PCI and cardiogenic shock indications grew 24% and 37%, respectively. Additionally, Impella contributed $2.6 million in revenues.
Market Prospects
Per research by CDC, nearly 610,000 people die from heart diseases each year in the United States.
Statista validates that the U.S. cardiovascular devices market is expected to reach $15.7 billion by 2021.
Thus, the latest development has been a well-timed one for Abiomed.
Key Picks
Some better-ranked stocks in the broader medical space are athenahealth , Masimo Corporation (MASI - Free Report) and Veeva Systems (VEEV - Free Report) .
athenahealth has a long-term expected earnings growth rate of 17.6%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Masimo’s long-term earnings growth rate is projected at 14.8%. The stock carries a Zacks Rank #2 (Buy).
Veeva Systems’ long-term earnings growth rate is estimated at 19.3%. The stock carries a Zacks Rank #1.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>